AP-1
Based on 1 Customer Validation
AP-1 is a targeted ALK PROTAC degrader. AP-1 effectively degrades various ALK fusion/mutation forms, including degradation of NPM-ALK (DC50 = 4.6 nM) and EML4-ALK (DC50 = 357.6 nM), and exhibits a typical hook effect at high concentrations. AP-1 inhibits phosphorylation of downstream STAT3, downregulates gene expression in the JAK-STAT pathway, and kills ALK-positive tumor cells via activating the caspase-3-dependent apoptosis pathway. AP-1 shows cytotoxicity against a variety of cancer cells and possesses anti-tumor activity. AP-1 can be used in research related to non-small cell lung cancer, neuroblastoma, and anaplastic large cell lymphoma.
(Pink: Anaplastic lymphoma kinase (ALK) ligand (HY-169482); Blue: Cereblon ligand (HY-10984); Black: linker).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 97.8%
- CAS No.: 3027918-96-0
- Formule: C39H40ClN9O8S
- Masse moléculaire:830.31
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
Description
IC50 & Target
[1]|
p-STAT3 |
Caspase-3 |
NPM-ALK 4.6 nM (DC50) |
EML4-ALK 357.6 nM (DC50) |
In Vitro
AP-1 (0.2-1200 nM; 0-24 h) potently degrades NPM-ALK in Karpas299 cells via the ubiquitin-proteasome system, with a DC50 of 4.6 nM and a maximum degradation rate of 92.28%, and inhibits the phosphorylation of downstream STAT3[1].
AP-1 (30 nM-10 μM; 72 h) exhibits potent cytotoxic activity against Karpas299 cells with an IC50 of 0.1265 nM, and also shows cytotoxic activity against 3122 cells[1].
AP-1 (16 h) degrades EML4-ALK in H3122 cells in a concentration-dependent manner, with a DC50 of 357.6 nM and a maximum degradation rate of 81.34%, and this degradation effect is reversible after drug withdrawal[1].
Treatment with AP-1 for 16 h downregulates the gene expression of oncogenic ALK and JAK-STAT pathways in H3122 cells[1].
AP-1 induces the colocalization of ALK and CRBN in H3122 cells, promoting the formation of the ternary complex required for PROTAC-mediated protein degradation[1].
AP-1 (1 nM-100 μM; 16 h) exhibits high selectivity for ALK, as it does not degrade the off-target proteins Aurora A or FAK in Karpas299 cells[1].
AP-1 (0.0001 nM-100 μM; 24-60 h) exhibits high selectivity for ALK-dependent cells, and shows extremely low cytotoxicity in non-ALK-dependent THP-1, HeLa and 293T cells compared with LDK378[1].
AP-1 kills H3122 cells via an apoptotic pathway involving caspase-3 activation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Karpas299 cells expressing NPM-ALK
-
Concentration:0.2, 0.4, 0.8, 1.5, 3, 6, 12, 25, 50, 100, 200, 400, 800 and 1200 nM (16 h); 100 nM (time-course); 1, 3, 10, 30, 100, 300 and 1000 nM (co-treated with 2 and 5 μM MG-132 (HY-13259), 16 h)
-
Incubation Time:16 h (concentration-dependent; proteasome inhibition); 0, 2, 4, 8, 16 and 24 h (time-course)
-
Result:Induced concentration-dependent degradation of NPM-ALK, with observable degradation at 10 nM, maximum degradation at ~300 nM, and slight reduction at 1 μM due to the hook effect.
Blocked NPM-ALK degradation when co-treated with MG-132, confirming proteasome-dependent activity.
Showed significant NPM-ALK degradation by 8 h, with maximum degradation at 16 h; p-ALK levels decreased with slower kinetics than total NPM-ALK.
Reduced p-STAT3 levels without affecting total STAT3.
Determined a DC50 of 4.6 nM and a maximum degradation level (Dₘₐₓ) of 92.28% for NPM-ALK from three repeated experiments.
-
Cell Line:Karpas299 cells expressing NPM-ALK
H3122 cells expressing EML4-ALK -
Concentration:30 nM, 100 nM, 300 nM, 1 μM, 3 μM, 10 μM
-
Incubation Time:72 h
-
Result:Exhibited potent cytotoxicity against Karpas299 cells, with an IC50 of 0.1265 nM.
Showed cytotoxicity 71.53% higher than ALK ligand A1 (IC50 0.4444 nM) and 80.63% higher than LDK378 (HY-15656) (IC50 0.6532 nM).
Exhibited cytotoxicity against H3122 cells.
-
Cell Line:Karpas299 cells expressing NPM-ALK
-
Concentration:1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 μM, 3 μM, 10 μM, 30 μM, 100 μM
-
Incubation Time:16 h
-
Result:Did not cause significant degradation of Aurora A or FAK proteins, even at concentrations up to 100 μM.
Parmacokinetics
| Species | Dose | Route | T1/2 | Cmax |
|---|---|---|---|---|
| Rat[1] | 1 mg/kg | i.v. | 0.73 h | 1114.80 μg/L |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NOD/SCID mice (6-8 weeks old) were subcutaneously inoculated with 1 × 106 NCI-H3122 cells in the right flank. When the tumors reached a mean volume of approximately 100 mm3, the treatment was initiated.
[1] -
Dosage:25 mg/kg; 50 mg/kg; 100 mg/kg
-
Administration:i.p.; once every 2 days
-
Result:Produced tumor growth inhibition (TGI) values of 56.51% at 25 mg/kg, 72.50% at 50 mg/kg, and 69.18% at 100 mg/kg.
Demonstrated equivalent antitumor efficacy to positive control LDK378 (25 mg/kg, TGI 57.66%) at 25 mg/kg dose.
Caused no significant body weight loss in treated mice.
Induced no notable liver or kidney function abnormalities at low-to-medium doses, with only slight increases in ALT, AST, and UREA-J indices at 100 mg/kg dose.
Chemical Information
-
CAS No. 3027918-96-0
-
Appearance Solid
-
Masse moléculaire 830.31
-
Formule C39H40ClN9O8S
-
Color Yellow to orange
-
SMILES
O=C1NC(C(CC1)N2C(C3=C(C2=O)C(NCC(N4CCN(CC4)C5=CC=C(C(OC)=C5)NC6=NC=C(C(NC7=C(S(=O)(C(C)C)=O)C=CC=C7)=N6)Cl)=O)=CC=C3)=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocole
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)